Supplementary Figure 2 from Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Le résumé fourni par la source

PDF file - 208K, (A) VEGFR2 is selectively expressed in tumor blood endothelial cells (BECs). Single cell suspension of pancreatic tumors of 12 weeks old Rip1Tag2 mice were prepared by Dispase digestion. For subsequent isolation of GLP-1R+ �-tumor cells (TC) and tumor-derived CD31+ blood vessel endothelial cells (BEC) by fluorescence-activated cell sorting (FACS), cells were stained with FITC-labeled glucagon-like peptide 1 receptor (GLP-1R) peptide ligand exendin-4 and with APC-CD31. Quantitative RT-PCR analysis verified VEGFR2 expression in CD31-positive BECs but not in TC. Cultured MS-1 cells express low levels of VEGFR2. (B) VEGFR2 is expressed in tumor-associated microvessels. Immunofluorescence staining of vessels in the pancreas of a Rip1Tag2 mouse treated with PLD. VEGFR2 is expressed in microvessels, but not in larger vessels or mature vessels. Vessels in the exocrine pancreas express lower levels of VEGFR2. Bar, 100 �m. The tumor tissue is delineated with a white line. Green = staining with anti-CD31, red = staining with anti-VEGFR2, blue = DAPI. Merge= overlay of single stainings.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.